News und Analysen

What's one of the biggest mistakes investors make? Selling stocks too soon. It's smarter to try to adhere to Warren Buffett's favorite holding period of "forever," or at least as close to that goal

BioNTech (NASDAQ: BNTX), the Germany-based biotech that scored big early in the pandemic era with the Comirnaty vaccine it developed with Pfizer, had some fresh news from the lab to report on

Nektar Therapeutics (NASDAQ: NKTR) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program. Instead

Just because a stock has been battered doesn't make it an automatic buy. That's only the case if it can bounce back, and in some cases, there are few good reasons to believe it can.

Take Teladoc

Shares in Arrowhead Pharmaceuticals (NASDAQ: ARWR) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned

Most development in artificial intelligence (AI) happens inside data centers, which are filled with thousands of purpose-designed chips from suppliers like Nvidia, Advanced Micro Devices, and

Viking Therapeutics (NASDAQ: VKTX) has intrigued investors over the past year and a half because it's involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk

There is no sugarcoating it: Vertex Pharmaceuticals (NASDAQ: VRTX) has faced significant issues this year that have sunk its stock price. The company's shares are down 2% year-to-date, while the S&P

The biotech industry can be highly volatile. Companies in the sector can sometimes see their shares double in a short period due to hitting important clinical milestones. Over a more extended

Investing on a budget can still be lucrative. And even though the best stocks tend to attract plenty of attention from investors who bid up their share prices, it's possible to find quality

There are a number of reasons to believe that Pfizer (NYSE: PFE) is an attractive dividend stock. The lofty 6.9% dividend yield is the obvious first reason, but the healthcare giant also has a long

The list of trillion-dollar stocks is small and doesn't feature a single medical company. That might change in the next decade, as several leading healthcare stocks have market caps that are inching

A buoyant stock market that keeps reaching new heights is great for the stocks already in our brokerage accounts. After a few strongly positive years, though, finding stocks that pay high dividend

Pfizer (NYSE: PFE) has become the dividend investor's siren song. With shares down 31% over the past five years and a current yield of 7%, the pharmaceutical giant offers one of the juiciest payouts

Some decisions require lengthy deliberations and extensive analysis. Others don't.

Three Fool.com contributors think they've identified pharmaceutical stocks in the latter category. Here's why they

Dividend stocks are a great way for investors to generate passive income that can be more reliable and predictable than investing in stocks for pure appreciation. While there are no guarantees in

Over the past several weeks, investors have been bombarded with a wave of updates as companies reported earnings results for the second calendar quarter. For technology investors, artificial

Dividend Champions are long-term winners. These companies have grown their dividends for at least 25 straight years. They don't have to be members of the S&P 500 (SNPINDEX: ^GSPC), which broadens

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even

If you're looking for growth stocks that could make dramatic gains in a short amount of time, the healthcare sector has you covered. Recently, investment bank analysts have been pounding the table

Numerous companies in the healthcare sector are feverishly busy developing obesity drugs, as these products have taken the medical world by storm. One of the more prominent developers

Nvidia (NASDAQ: NVDA) closed at $180.12, down 0.82%. Trading volume surged to 278 million shares, well above the 178 million three-month average. The chipmaker, valued at $4.4 trillion, traded as

In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), IREN (NASDAQ: IREN), Advanced Micro Devices (NASDAQ: AMD), and other semiconductor stocks. To learn more, check out the

The healthcare industry is a good place to look for strong dividend-paying stocks. Many companies in the sector offer products that are consistently in demand, regardless of the state of the